TIRZEPATIDE
Tirzepatide activates GIP and GLP-1 receptors. Unlike investigational metabolic peptides, it has large randomized trial programs and FDA-approved products for diabetes and obesity.
Approved medicine.
The interesting question is no longer whether tirzepatide works—it is where the evidence stops and broader claims begin.
Two incretin pathways.
One approved medicine.
Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist with extensive randomized human evidence.
It is the active ingredient in FDA-approved medicines used for type 2 diabetes and chronic weight management. That makes Tirzepatide fundamentally different from many compounds discussed in biohacking: the core efficacy story is not speculative.
Tirzepatide works on two appetite and metabolic pathways, helping many people dramatically reduce hunger while improving blood-sugar control and driving substantial weight loss.
A high evidence bar.
SURPASS established strong glucose-lowering efficacy in type 2 diabetes, while the SURMOUNT program established substantial weight loss in obesity. In SURMOUNT-5, tirzepatide produced a 20.2% mean weight reduction at 72 weeks and outperformed semaglutide in a randomized head-to-head obesity trial.
Different strengths. No head-to-head trial yet.
Cross-trial comparisons suggest a more nuanced story than “Retatrutide is better.” Tirzepatide has the stronger raw A1C result in the trials below; Retatrutide has produced the larger obesity weight-loss result.
Tirz vs Reta: what the data actually say
Separate trials, different populations, baselines, durations and estimands. This is not a randomized Tirzepatide-vs-Retatrutide comparison.
A1C reduction · type 2 diabetes trials
Tirzepatide: SURPASS-2, 40 weeks, baseline mean A1C 8.28%. Retatrutide: TRIUMPH-2, 80 weeks, baseline mean A1C 7.71%. Baseline A1C affects how much room there is to fall.
Mean weight loss · obesity trials without diabetes
Tirzepatide: SURMOUNT-5 maximum tolerated dose at 72 weeks. Retatrutide: TRIUMPH-1 efficacy estimand at 80 weeks. Separate trials—not proof of superiority.
Open the Retatrutide evidence profile →
Where confidence is earned.
What people are actually reporting.
Tirzepatide has an FDA-labeled dosing framework. The community conversation is mostly about modifying the pace—not replacing the underlying once-weekly evidence base.
Across current GLP-1 communities, people frequently describe holding 2.5 mg or 5 mg longer, stepping up more slowly, or reducing again after side effects or after reaching a goal. This is a community pattern, not a validated alternative dosing protocol.
The strongest efficacy and safety evidence comes from studied once-weekly regimens and approved product labeling—not from microdosing or split-dose protocols. Tirzepatide is unusual in this Index because we can place community experimentation directly beside a well-defined clinical dosing framework.
Narrow for approved use. Wider outside it.
The evidence gap is relatively narrow for approved tirzepatide used in studied populations. It widens when claims move into unstudied wellness uses, individualized formulations or assumptions about non-approved products.